newsfilter
← Latest News
GlobeNewswire·

ZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkinson's Disease

Study supported by the Michael J. Fox Foundation through a grant awarded to ZyVersa and leading inflammasome experts at University of Miami Miller School of Medicine who conducted the study.Parkinson's Disease (PD)